<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273532</url>
  </required_header>
  <id_info>
    <org_study_id>CR017602</org_study_id>
    <secondary_id>R331333PAI1063</secondary_id>
    <nct_id>NCT01273532</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet</brief_title>
  <official_title>A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study to Assess the Bioequivalence of Tapentadol Given as Two 50-mg Extended-Release, Tamper-Resistant Formulation (TRF) Tablets Relative to One 100-mg Extended-Release TRF Tablet in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of a 100-mg tapentadol (CG5503)&#xD;
      dose administered as two 50-mg ER, TRF tablets relative to one 100-mg ER TRF tablet in&#xD;
      healthy Japanese male participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label (all people know the identity of the intervention), single-center,&#xD;
      randomized (the study drug is assigned by chance), 2-way crossover study (participants may&#xD;
      receive different interventions sequentially during the trial). All participants will receive&#xD;
      a single 100-mg dose of tapentadol (CG5503) during 2 periods, in randomized order, as two&#xD;
      50-mg TRF tablets and one 100-mg TRF tablet. All participants will be randomly assigned to 1&#xD;
      of 2 possible treatment sequences and receive both of the following treatments, 1 in each&#xD;
      period:&#xD;
&#xD;
      Treatment A: two tapentadol (CG5503) ER 50-mg TRF tablets, administered as a single oral dose&#xD;
      under fasted condition Treatment B: one tapentadol (CG5503) ER 100-mg TRF tablet,&#xD;
      administered as a single oral dose under fasted condition Each period will be separated by 7&#xD;
      - 14 days&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile, as measured by Cmax, tmax, AUC, t1/2, kel, AUMC and MRT</measure>
    <time_frame>Two days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Time of screening to end of treatment (up to 5.5 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER 50-mg TRF 100 mg TRF single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tapentadol (CG5503) ER 100-mg TRF 100mg TRF single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER 100-mg TRF</intervention_name>
    <description>100mg TRF single oral dose</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tapentadol (CG5503) ER 50-mg TRF</intervention_name>
    <description>100 mg TRF single oral dose</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese participants who have resided outside of Japan for no more than 5 years and&#xD;
             whose parents and maternal and paternal grandparents are Japanese, as determined by&#xD;
             participant's verbal report&#xD;
&#xD;
          -  Deemed healthy on the basis of prestudy physical examination, medical history&#xD;
             (including smoking habits), 12-lead electrocardiogram (ECG), vital signs, and clinical&#xD;
             laboratory parameters (serum chemistry, serology and hematology) performed within 21&#xD;
             days before study drug administration.&#xD;
&#xD;
          -  Must not impregnate their partners&#xD;
&#xD;
          -  Body mass index (BMI) (weight [kg]/height [m2]) between 18.5 and 25 kg/m2, inclusive,&#xD;
             and body weight not less than 50 kg&#xD;
&#xD;
          -  Blood pressure (after the participant is supine for 5 minutes) between 100 and 140&#xD;
             mmHg systolic, inclusive, and between 50 and 90 mmHg diastolic, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of seizure disorder or epilepsy or ¿mild or moderate traumatic brain injury,&#xD;
             stroke, transient ischemic attack, or brain neoplasm within 1 year of screening&#xD;
&#xD;
          -  history of ¿severe traumatic brain injury (consisting of 1 or more of the following:&#xD;
             brain contusion&#xD;
&#xD;
          -  intracranial hematoma&#xD;
&#xD;
          -  or episode(s) of more than 24 hours duration of unconsciousness or posttraumatic&#xD;
             amnesia) within 15 years of screening, or history of ¿severe traumatic brain injury&#xD;
             resulting in ongoing sequelae suggesting transient changes in consciousness or&#xD;
             symptoms suggestive thereof&#xD;
&#xD;
          -  History of a gastrointestinal disease affecting absorption, gastric surgery or history&#xD;
             of or current significant medical illness&#xD;
&#xD;
          -  History of clinically significant allergies, especially known&#xD;
             hypersensitivity/intolerance or contraindications to opioids, opioid antagonists&#xD;
             (e.g., naloxone), benzodiazepines (e.g., diazepam, clonazepam, lorazepam), any study&#xD;
             drug formulation component, any of the excipients of the formulation, or heparin&#xD;
             (should the use of a heparin lock be necessary)&#xD;
&#xD;
          -  History of, or a reason to believe a participant has a history of lifetime opioid&#xD;
             abuse, or drug or alcohol abuse within the past 5 years&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>March 12, 2012</last_update_submitted>
  <last_update_submitted_qc>March 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2012</last_update_posted>
  <responsible_party>
    <name_title>Senior Director, Clinical Leader</name_title>
    <organization>Johnson &amp; Johnson Pharmaceutical Research and Development, L.L.C.</organization>
  </responsible_party>
  <keyword>tapentadol</keyword>
  <keyword>NUCYNTA</keyword>
  <keyword>CG5503</keyword>
  <keyword>R331333</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>healthy volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tapentadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

